The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country
The European Journal of Health Economics , Volume 13 - Issue 5 p. 663- 676
Background/aims: Chronic hepatitis B (CHB) infection is a serious public health problem due to its potential liver disease sequelae and highly expensive medical costs such as the need for liver transplantation. The aim of this study was to quantify the burden of active CHB in terms of mortality and morbidity, the eligibility of antiviral treatment and to assess various treatment scenarios and possible salvage combinations for cost-effectiveness. Methods: A population cohort from a large data base of chronic hepatitis B patients was constructed and stratified according to 10-year age groups, the prevalence of HBsAg, HBV DNA level, ALT level, HBeAg status and the presence of cirrhosis. An age-specific Markov model for disease progression and cost-effectiveness analysis was constructed and calibrated for the specific population setting. Results: Of about 3.2 million estimated HBsAg carriers, 25 % are eligible for treatment. If the active cohort remains untreated, 31 % will die due to liver related complications. Within a 20-year period, 11 % will have developed decompensated cirrhosis, 12 % liver cancer and 6 % will need liver transplantation. Quality adjusted life years (QALYs) for the no treatment scenario ranged from 9.3 to 14.0. For scenarios with antiviral treatment, QALYs ranged from 9.9 to 14.5 for lamivudine, 13.0-17.5 for salvage therapy, and 16.6-19.0 for the third generation drugs entecavir and tenofovir. Conclusion: In a country with considerable amount of active CHB patients, monotherapy with a highly potent third generation drug has the most health-gain, and is cost-effective in both HBeAg-positive and negative in all stages of liver disease.
|, , , ,|
|The European Journal of Health Economics|
|Organisation||Erasmus MC: University Medical Center Rotterdam|
Toy, M, Onder, G, Idilman, R, Kabacam, G, Richardus, J.H, Bozdayi, A.M, … Yurdaydin, C. (2012). The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country. The European Journal of Health Economics, 13(5), 663–676. doi:10.1007/s10198-012-0413-8